Alector is developing next-generation therapies for neurodegenerative diseases through its proprietary Alector Brain Carrier (ABC) platform, designed to improve drug delivery across the blood–brain barrier. 🔹 Key Highlights 🧠 ABC Platform: Alector's technology is designed to improve delivery of therapies into the brain. 💊 AL137: Brain-enabled anti-amyloid beta antibody targeting Alzheimer's disease. 🧬 AL164: Tau-targeting siRNA being developed for Alzheimer's and other tauopathies. 🤝 Genentech Partnership: Genentech, part of Roche, licensed AL050, including $100M upfront, up to $1.17B in additional milestones, plus royalties. 💰 Capital Position: Alector raised $75M gross through a common-stock offering and had $172.8M in cash and investments as of June 30, 2026. ⚠️ Clinical Risk: The Phase 2 AL101 Alzheimer's trial was discontinued following an interim futility analysis. 🚀 Upcoming Catalysts: AL137 IND submission is targeted for Q1 2027, with first-in-human dosing targeted by April 2027. 📅 Runway: Management said the Genentech deal extends the company's runway into 2029. 💡 Why It Matters The Genentech partnership provides external validation for Alector's brain-delivery technology while bringing upfront capital and potential milestone payments. The major opportunity now centers on advancing AL137 and the broader ABC platform toward clinical testing, although early-stage development and dilution remain important risks. 🚀 ThinkSabio Start Your 7-Day FREE ThinkSabio Trial https://www.thinksabio.com/